Health-related quality of life in pre-pubertal children with pediatric growth hormone deficiency: 12-month results from a Phase 3 clinical trial of once-weekly somatrogon versus once-daily somatropin

Conclusion: Treatment for 12 months with once-weekly somatrogon or once-daily somatropin resulted in comparable improvements in HRQoL among children with pGHD. Lower HRQoL perceived by parents/caregivers possibly reflect children's tendency to emphasize adaptation. These results suggest that evaluation of HRQoL could help support treatment decisions in children with pGHD treated with growth hormone.NCT02968004.PMID:38053515 | DOI:10.1080/03007995.2023.2290623
Source: Current Medical Research and Opinion - Category: Research Authors: Source Type: research